- Immunotherapy with immune checkpoint inhibitors (ICIs) was less effective in patients with NSCLC and bone metastases than in those without bone metastases, regardless of tumor histology.
Why this matters
- Up to 30% of patients with NSCLC have bone metastases at NSCLC diagnosis, and another 35%-40% develop the lesions after diagnosis.
- Pretreated patients with nonsquamous NSCLC (n=1588) and squamous NSCLC (n=371) in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to bone metastases.
- Funding: None.
- 39% of nonsquamous patients and 32% of squamous patients had bone metastases.
- Nonsquamous patients with bone metastases had a significantly lower objective response rate (ORR; 12% vs 23%; P<.0001 and pfs vs months p os>
- Squamous patients with bone metastases also had significantly lower ORR (13% vs 22%; P=.04) and shorter PFS (2.7 vs 5.2 months; P<.0001 os vs months p>
- After multivariable analysis, bone metastases were associated with higher mortality (nonsquamous HR, 1.50 [P<.0001 and squamous hr pfs orr>
- Retrospective study.